Scholarly Articles on Reta

[keangkong]

Below are some hyperlinked articles without pay walls on retatrutide. The article by Jastreboff, et al., describes a 48-week, phase 2 trial of reta.

Abdul-Rahman, et al., The power of three - Retatrutide's role in modern obesity and di, https://doi.org/10.1016/j.ejphar.2024.177095.

Alfaris, et al. (2024) GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity - a narrative review. EClinicalMedicine, 75, 102782.

Ansari, et al. (2024). Targeting the incretin system in obesity and type 2 diabetes mellitus. Nature Reviews Endocrinology, 20, 447-459, Rev Endocrinol 20, 447–459.

Bailey, et al. (2024). Recent advances in peptide-based therapies for obesity and type 2 diabetes. Peptides 173, 171149.

Brzozowska, et al. (2024). Retatrutide-revolutionary recently developed GLP agonist-literature review. Quality in Sport, 15, 52125-52125.

Deravi, et al., The “Weight” for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity (2024) 40(6) J. Pharm. Technol. 300.

Gutgesell , et al. (2024). Dual and Triple Incretin-Based Co-agonists - Novel Therapeutics for Obesity and Diabetes (2024) Diabetes Therapy, 15, 1069–1084.

Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 389(6), 514–526.

Kaur & Misra (2024). A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. Eur. J. Clin. Pharmacol. 80, 669-676.

Le Roux & Mondoh (2024). Treatment of obesity with medications binding the glucagon-like peptide 1 receptor - what is the current state of play[Q] Expert Opinion on Pharmacotherapy, 25(2), 131-138.

Martins, et al. (2024). Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus. Exploration Drug Sci., 2, 126-143.

Moiz, et al. (2025). Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes. Annals of Internal Medicine.

Otvos (2024). The latest trends in peptide drug discovery and future challenges. Expert Opinion on Drug Discovery, 19(8), 869-872.

Pasqualotto, et al. (2024). Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers - A systematic review and meta-analysis of randomized controlled trials. Metabolism Open, 24, 100321.

Rosenkilde (2024). Advances in incretin-based therapeutics for obesity. Nature Reviews Endocrinology, 20, 67-68.

Rosenstock, et al., Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes - a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial
conducted in the USA (2023) The Lancet, 402(10401), 529–544.

Ruder, At ObesityWeek, More Data and Questions About Semaglutide, Tirzepatide, and Retatrutide (2024) 331(1) JAMA 9.

Sanyal, et al., Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease - a randomized phase 2a trial (2024) 30 Nature Medicine 2037.

Sutherby, It Is a Huge Market. The Pipeline Is Full. More GLP-1s Are On Their Way (Jun. 3, 2024) 34(6) Managed Healthcare Executive.

Tetelbaun, et al., The First Triple Agonist for Antiobesity - Retatrutide (pre-publication, 2024) Cardiology in Review.

Urva, et al., LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes - a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial (2022) 400(10366 Lancet 1869.

2025-01-10: Edited twice to include several more sources.

 

[DwightTheDelight]

I'm going to click your links, Kongy, but if this is primate porn....again ...

 

[keangkong]

I'm going to click your links, Kongy, but if this is primate porn....again ...

There is difference between erotic and pornographic.

 

[keangkong]

I edited the original post to include several more articles on reta. I can't post on actual experiences since I haven't started on it yet. Actually, my body is doing better on tirzepatide than it did previously and I'm not sure that I'll end up using the reta I bought. But I'm still interested because it's my Plan B.

 

[keangkong]

I'm adding two more articles. Both discuss more than one drug but discuss reta.

Rosenkilde (2024). Advances in incretin-based therapeutics for obesity. Nature Reviews Endocrinology, 20, 67-68, doi.org/10.1038/s41574-023-00938-w.

Ansari, et al. (2024). Targeting the incretin system in obesity and type 2 diabetes mellitus. Nature Reviews Endocrinology, 20, 447-459, Rev Endocrinol 20, 447–459. doi.org/10.1038/s41574-024-00979-9.